Independent administration of long-acting somatostatin analogues (SSAs) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET): Potential savings of increased uptake in the UK National Health Service (NHS)

#3221

Introduction: Lanreotide Autogel (LAN) and octreotide long-acting release (OCT) are long-acting SSAs used to treat GEP-NET. Only LAN is approved for independent (self/partner) injection, obviating need for in-person provider visits. Uptake of this option, already convenient for some patients, has accelerated in the UK amid the COVID-19 pandemic, with delivery modes reorganized in line with “COVID-19 rapid guideline: delivery of systemic anticancer treatments [NG161]” published for the NHS.

Aim(s): To quantify cost savings and visits avoided with increased uptake of independent administration for the treatment of GEP-NET in the UK.

Materials and methods: A budget impact model was developed from the UK NHS perspective to consider costs of SSA drug acquisition and administration, based on publicly available sources. Here, we describe a dedicated scenario from this model designed to understand potential savings generated when a patient with GEP-NET treated with OCT switches to LAN administered via independent injection.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Harrow B, Cristeau O, Clay E, Francois C, Frankcom I,

Keywords: somatostatin analogues, GEP-NET, HEOR, covid-19,